S
39.35
2.97 (8.16%)
| 前收盘价格 | 36.38 |
| 收盘价格 | 36.46 |
| 成交量 | 418,305 |
| 平均成交量 (3个月) | 384,492 |
| 市值 | 1,836,737,792 |
| 价格/销量 (P/S) | 17.37 |
| 股市价格/股市净资产 (P/B) | 4.64 |
| 52周波幅 | |
| 利润日期 | 9 Nov 2026 |
| 营业利益率 (TTM) | -11,831.05% |
| 稀释每股收益 (EPS TTM) | -1.78 |
| 季度收入增长率 (YOY) | -30.90% |
| 总债务/股东权益 (D/E MRQ) | 6.25% |
| 流动比率 (MRQ) | 32.19 |
| 营业现金流 (OCF TTM) | -74.10 M |
| 杠杆自由现金流 (LFCF TTM) | -25.69 M |
| 资产报酬率 (ROA TTM) | -17.20% |
| 股东权益报酬率 (ROE TTM) | -30.96% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Septerna, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-0.3
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -0.33 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 2.64% |
| 机构持股比例 | 105.46% |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合